Albireo Pharma CEO and leadership

Ronald 'Ron' Cooper is a Board Member at Generation Bio Co; Board Member at ALBIREO PHARMA, INC.; and Board Member at Genocea and is based in Boston, Massachusetts. He has worked as President/CEO at ALBIREO PHARMA, INC. and President:Europe at Bristol-Myers Squibb. Ronald attended Saint Francis Xavier University between 1981 and 1985.

Jan Mattsson, PhD, has 19 years of experience in the drug industry. He has extensive experience in molecular pharmacology as well as a broad, in depth knowledge of the gastrointestinal (GI) area. In the past he has been responsible for drug discovery and early development activities in various GI disease areas and also in osteoporosis. He has a track record of success including the delivery of a number of lead optimisation projects candidate drugs spanning several indications.

Simon Harford is a Senior VP:Finance at GSK and CFO/Treasurer at ALBIREO PHARMA, INC. and is based in Waltham, Massachusetts. He has worked as Board Member at Glaxosmithkline Pharmaceutical, CFO:Europe & Middle East at ELI LILLY & CO, and VP/Controller at Avon Products. Simon studied at University of Virginia Darden School of Business between 1986 and 1988.

Pamela Stephenson is a Chief Commercial Officer at ALBIREO PHARMA, INC. and Board Member at ZYNERBA PHARMACEUTICALS, INC. and is based in Boston, Massachusetts. She has worked as VP:Cystic Fibrosis Marketing at VERTEX PHARMACEUTICALS INC; VP:Global Market Access at VERTEX PHARMACEUTICALS INC; and Senior Associate, Payer Strategy at Covance. Pamela attended Brown University between 1985 and 1989, Brown University in Providence in the State of Rhode Island & Providence Plantat, and Boston University School of Public Health between 1991 and 1992.

Jason G Duncan is a Chief Legal Officer/General Counsel/Secy at ALBIREO PHARMA, INC. and is based in Greater Boston Area. He has worked as Associate at Peabody & Arnold LLP; General Counsel at Stallergenes Greer PLC; and Secretary/General Counsel at ALBIREO PHARMA, INC.. Jason attended Suffolk University Law School between 1998 and 2001, Kent School between 1988 and 1991, and Fay School between 1985 and 1988.

Martha Carter was appointed Chief Regulatory Officer of Aegerion in February 2011, bringing over 30 years of regulatory affairs experience in prescription and over-the-counter drugs, biologics, biotechnology products, and medical devices. Prior to joining Aegerion, Martha was Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. where she was responsible for the company's worldwide regulatory and quality functions. Prior to this role, she was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to that, Martha was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. In this role, she led the company's regulatory and quality control functions for both commercial and investigational drug products. Martha is a Fellow of the Regulatory Affairs Professionals Society, and is a past President and Chairman of the Board. She is also a former member of the Editorial Advisory Board for Applied Clinical Trials and BioPharm. Martha holds a B.A. in Biology from Northeastern University.

Global HR business executive with experience ranging from small biotech to large Fortune 500 organizations across the healthcare continuum, including biopharmaceutical, medical device, medical technology, consumer product, and insurance. Builds strong partnerships with CEO, senior executives, and employees to drive culture change, innovation, growth and business performance. Visionary HR leader with deep technical HR expertise in talent, organizational development, executive compensation, and building high-performing teams. Board-level experience as management liaison in both public and private equity settings, and mergers and acquisitions for small and large-scale acquisitions.

Jan Mattsson, PhD, has 19 years of experience in the drug industry. He has extensive experience in molecular pharmacology as well as a broad, in depth knowledge of the gastrointestinal (GI) area. In the past he has been responsible for drug discovery and early development activities in various GI disease areas and also in osteoporosis. He has a track record of success including the delivery of a number of lead optimisation projects candidate drugs spanning several indications.

Ronald 'Ron' Cooper is a Board Member at Generation Bio Co; Board Member at ALBIREO PHARMA, INC.; and Board Member at Genocea and is based in Boston, Massachusetts. He has worked as President/CEO at ALBIREO PHARMA, INC. and President:Europe at Bristol-Myers Squibb. Ronald attended Saint Francis Xavier University between 1981 and 1985.

Jan Mattsson, PhD, has 19 years of experience in the drug industry. He has extensive experience in molecular pharmacology as well as a broad, in depth knowledge of the gastrointestinal (GI) area. In the past he has been responsible for drug discovery and early development activities in various GI disease areas and also in osteoporosis. He has a track record of success including the delivery of a number of lead optimisation projects candidate drugs spanning several indications.